Enodar Biologic, Zymark

Premium

Fred Hutchinson Cancer Research Center spin-off Enodar Biologic has launched its True Discovery genomic data-analysis services for the pharmaceutical and biotechnology industries.

Components of the service, which comprises patent-pending technology licensed from the Fred Hutchinson Cancer Research Center, are indented to “reduce genomic data backlogs, to provide an independent means to verify and validate biomarker discoveries, and to identify a higher number of quality biomarkers for investigation,” Enodar said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.